<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MARBETA L KIT- betamethasone sodium phosphate, betamethasone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidine iodine, isopropyl alcohol 
			 </strong><br>Asclemed USA, Inc.<br></p></div>
<h1>Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, 6 mg/mL</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx Only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP is a sterile aqueous suspension containing betamethasone 3 mg per milliliter as betamethasone sodium phosphate, and betamethasone acetate 3 mg per milliliter.  Inactive ingredients per mL: dibasic sodium phosphate 7.1 mg; monobasic sodium phosphate 3.4 mg; edetate disodium 0.1 mg; and benzalkonium chloride 0.2 mg as a preservative.  The pH is adjusted to between 6.8 and 7.2.</p>
<p>The formula for betamethasone sodium phosphate is C<span class="Sub">22</span>H<span class="Sub">28</span>FNa<span class="Sub">2</span>O<span class="Sub">8</span>P and it has a molecular weight of 516.41.  Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate).</p>
<p>The formula for betamethasone acetate is C<span class="Sub">24</span>H<span class="Sub">31</span>FO<span class="Sub">6</span> and it has a molecular weight of 434.50.  Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-acetate.</p>
<p>The chemical structures for betamethasone sodium phosphate and betamethasone acetate are as follows:</p>
<div class="Figure">
<img alt="50caa3fb-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-01.jpg"><p class="MultiMediaCaption"> betamethasone sodium phosphate</p>
</div>
<div class="Figure">
<img alt="50caa3fb-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-02.jpg"><p class="MultiMediaCaption"> betamethasone acetate</p>
</div>
<p>Betamethasone sodium phosphate is a white to practically white, odorless powder, and is hygroscopic.  It is freely soluble in water and in methanol, but is practically insoluble in acetone and in chloroform.</p>
<p>Betamethasone acetate is a white to creamy white, odorless powder that sinters and resolidifies at about 165ºC, and remelts at about 200ºC-220ºC with decomposition.  It is practically insoluble in water, but freely soluble in acetone, and is soluble in alcohol and in chloroform.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract.  Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.  Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems.  A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.</p>
<p>Betamethasone sodium phosphate, a soluble ester, provides prompt activity, while betamethasone acetate is only slightly soluble and affords sustained activity.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">When oral therapy is not feasible, the <span class="Bold">intramuscular use</span> of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows:</p>
<p><span class="Bold">Allergic States</span> Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions, perennial or <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span>.</p>
<p><span class="Bold">Dermatologic Diseases</span> <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis, exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span> Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer, nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
<p>Hydrocortisone or cortisone is the drug of choice in primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span>.  Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.</p>
<p><span class="Bold">Gastrointestinal Diseases</span> To tide the patient over a critical period of the disease in <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p><span class="Bold">Hematologic Disorders</span> Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, selected cases of secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Miscellaneous</span> Trichinosis with neurologic or myocardial involvement, tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.</p>
<p><span class="Bold">Neoplastic Diseases</span> For palliative management of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
<p><span class="Bold">Nervous System</span> Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>; <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> or craniotomy.</p>
<p><span class="Bold">Ophthalmic Diseases</span> Sympathetic ophthalmia, <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and ocular inflammatory conditions unresponsive to topical corticosteroids.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Diseases</span></span> To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
<p><span class="Bold">Respiratory Diseases</span> Berylliosis, fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy, idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>, symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
<p><span class="Bold">Rheumatic Disorders</span> As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>; acute rheumatic carditis; <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>; <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy).  For the treatment of <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p>The <span class="Bold">intra-articular or soft tissue administration</span> of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">epicondylitis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</p>
<p>The <span class="Bold">intralesional administration</span> of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for <span class="product-label-link" type="condition" conceptid="141933" conceptname="Alopecia areata">alopecia areata</span>; <span class="product-label-link" type="condition" conceptid="4066824" conceptname="Discoid lupus erythematosus">discoid lupus erythematosus</span>; keloids; localized hypertrophic, infiltrated, inflammatory lesions of <span class="product-label-link" type="condition" conceptid="4277253" conceptname="Granuloma annulare">granuloma annulare</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, lichen simplex chronicus (<span class="product-label-link" type="condition" conceptid="4148920" conceptname="Neurodermatitis">neurodermatitis</span>), and psoriatic plaques; necrobiosis lipoidica diabeticorum.</p>
<p>Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is contraindicated in patients who are hypersensitive to any components of this product.  Intramuscular corticosteroid preparations are contraindicated for <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="be10f9b4-3ec9-4801-81e4-dd889cc69bc4"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS
</span></h1>
<div class="Section">
<a name="s5"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General
</span></h2>
<p class="First">Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension should not be administered intravenously.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy (see <a href="#b00467c6-4ca5-4724-9e56-75cba74a5373">ADVERSE REACTIONS</a>).</p>
<p>In patients on corticosteroid therapy subjected to any unusual stress, hydrocortisone or cortisone is the drug of choice as a supplement during and after the event.</p>
</div>
<div class="Section">
<a name="s6"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Cardio-Renal
</span></h2>
<p class="First">Average and large doses of corticosteroids can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium.  These effects are less likely to occur with the synthetic derivatives except when used in large doses.  Dietary salt restriction and potassium supplementation may be necessary.  All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
</div>
<div class="Section">
<a name="s7"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Endocrine
</span></h2>
<p class="First">Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients.  Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
</div>
<div class="Section">
<a name="s8"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> 
</span></h2>
<div class="Section">
<a name="s9"></a><a name="section-6.4.1"></a><p></p>
<h3>General</h3>
<p class="First">Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than are healthy individuals.  There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used.  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents.  These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe.  With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.  Corticosteroids may also mask some signs of current <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section">
<a name="s10"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal Infections</span></h3>
<p class="First">Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions.  There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see <a href="#b6519cea-238e-4fb8-b5ab-c63aa06e2770">PRECAUTIONS, Drug Interactions, Amphotericin B Injection and Potassium-Depleting Agents</a> section).</p>
</div>
<div class="Section">
<a name="s11"></a><a name="section-6.4.3"></a><p></p>
<h3>Special Pathogens</h3>
<p class="First">Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by <span class="Italics">Amoeba, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis</span>, and <span class="Italics">Toxoplasma</span>.  It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>.  In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
</div>
<div class="Section">
<a name="s12"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h3>
<p class="First">The use of corticosteroids in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur.  During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
</div>
<div class="Section">
<a name="b946fdf2-7f2c-41ee-be5d-a40b55dacc75"></a><a name="section-6.4.5"></a><p></p>
<h3>Vaccination</h3>
<p class="First"><span class="Bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.  Killed or inactivated vaccines may be administered.  However, the response to such vaccines cannot be predicted.</span>  Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, eg, for Addison’s disease.</p>
</div>
<div class="Section">
<a name="s13"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral Infections</span></h3>
<p class="First">Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in pediatric and adult patients on corticosteroids.  In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure.  The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.  If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated.  If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated.  (See the respective package inserts for complete VZIG and IG prescribing information.)  If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents should be considered.</p>
</div>
</div>
<div class="Section">
<a name="b9bc56f8-816f-4c6d-a346-5f3ebe099833"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Neurologic
</span></h2>
<p class="First">Reports of severe medical events have been associated with the intrathecal route of administration (see ADVERSE REACTIONS, <a href="#b63d5d91-dd53-4c94-9c2f-efb3663c1031">Gastrointestinal</a> and <a href="#bbe851ba-8b7d-4d20-871c-5e3d3951fb5d">Neurologic/Psychiatric</a> sections).</p>
<p>Results from one multicenter, randomized, placebo controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early mortality (at 2 weeks) and late mortality (at 6 months) in patients with cranial <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> who were determined not to have other clear indications for corticosteroid treatment. High doses of corticosteroids, including Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>.</p>
</div>
<div class="Section">
<a name="s14"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Ophthalmic
</span></h2>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses.  The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes.  Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s15"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s16"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General
</span></h2>
<p class="First">This product, like many other steroid formulations, is sensitive to heat.  Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment.  When reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposi’s <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.  Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section">
<a name="s17"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Cardio-Renal
</span></h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section">
<a name="s18"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Endocrine
</span></h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage.  This type of relative insufficiency may persist for months after discontinuation of therapy.  Therefore, in any situation of stress occurring during that period, naturally occurring glucocorticoids (hydrocortisone cortisone), which also have salt-retaining properties, rather than betamethasone, are the appropriate choices as replacement therapy in adrenocorticoal deficiency states.</p>
</div>
<div class="Section">
<a name="s19"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Gastrointestinal
</span></h2>
<p class="First">Steroids should be used with caution in active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, since they may increase the risk of a perforation.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent.</p>
<p>There is an enhanced effect of corticosteroids in patients with cirrhosis.</p>
</div>
<div class="Section">
<a name="s20"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">Intra-Articular and Soft Tissue Administration
</span></h2>
<p class="First">Intra-articular injected corticosteroids may be systematically absorbed.</p>
<p>Appropriate examination of any joint fluid present is necessary to exclude a septic process.</p>
<p>A marked increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> accompanied by <span class="product-label-link" type="condition" conceptid="4200520" conceptname="Neck swelling">local swelling</span>, further restriction of joint motion, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are suggestive of <span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">septic arthritis</span>.  If this complication occurs and the diagnosis of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> is confirmed, appropriate antimicrobial therapy should be instituted.</p>
<p>Injection of a steroid into an infected site is to be avoided.  Local injection of a steroid into a previously injected joint is not usually recommended.</p>
<p>Corticosteroid injection into unstable joints is generally not recommended.</p>
<p>Intra-articular injection may result in damage to joint tissues (see <a href="#b8415b03-c806-4dfc-9047-abc18950a7e2">ADVERSE REACTIONS, Musculoskeletal</a> section).</p>
</div>
<div class="Section">
<a name="s21"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Musculoskeletal
</span></h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (ie, decreasing absorption and increasing excretion) and inhibition of osteoblast function.  This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age.  Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (ie, postmenopausal women) before initiating corticosteroid therapy.</p>
</div>
<div class="Section">
<a name="b1eece69-2e2b-4a18-92e8-d09614247e42"></a><a name="section-7.7"></a><p></p>
<h2><span class="Bold">Neuro-Psychiatric
</span></h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease.  The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see <a href="#bb68735a-38db-46c7-adcb-b1c3a2337190">DOSAGE AND ADMINISTRATION</a>).  An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders with neuromuscular transmission (eg, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy of neuromuscular blocking drugs (eg, pancuronium).  This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>.  Elevation of creatinine kinase may occur.  Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations.  Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
</div>
<div class="Section">
<a name="s22"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">Ophthalmic
</span></h2>
<p class="First">Intraocular pressure may become elevated in some individuals.  If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s23"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">Information for Patients
</span></h2>
<p class="First">Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Persons who are on corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>.  Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s24"></a><a name="section-7.10"></a><p></p>
<h2><span class="Bold">Drug Interactions
</span></h2>
<div class="Section">
<a name="s25"></a><a name="section-7.10.1"></a><p></p>
<h3>Aminoglutethimide</h3>
<p class="First">Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.</p>
</div>
<div class="Section">
<a name="b6519cea-238e-4fb8-b5ab-c63aa06e2770"></a><a name="section-7.10.2"></a><p></p>
<h3>Amphotericin B Injection and Potassium-Depleting Agents</h3>
<p class="First">When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin-B, diuretics), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
<div class="Section">
<a name="s26"></a><a name="section-7.10.3"></a><p></p>
<h3>Antibiotics</h3>
<p class="First">Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.</p>
</div>
<div class="Section">
<a name="s27"></a><a name="section-7.10.4"></a><p></p>
<h3>Anticholinesterases</h3>
<p class="First">Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.  If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
</div>
<div class="Section">
<a name="s28"></a><a name="section-7.10.5"></a><p></p>
<h3>Anticoagulants, Oral</h3>
<p class="First">Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.  Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
</div>
<div class="Section">
<a name="s29"></a><a name="section-7.10.6"></a><p></p>
<h3>Antidiabetics</h3>
<p class="First">Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
</div>
<div class="Section">
<a name="s30"></a><a name="section-7.10.7"></a><p></p>
<h3>Antitubercular Drugs</h3>
<p class="First">Serum concentrations of isoniazid may be decreased.</p>
</div>
<div class="Section">
<a name="s31"></a><a name="section-7.10.8"></a><p></p>
<h3>Cholestyramine</h3>
<p class="First">Cholestyramine may increase the clearance of corticosteroids.</p>
</div>
<div class="Section">
<a name="s32"></a><a name="section-7.10.9"></a><p></p>
<h3>Cyclosporine</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently.  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
</div>
<div class="Section">
<a name="s33"></a><a name="section-7.10.10"></a><p></p>
<h3>Digitalis Glycosides</h3>
<p class="First">Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
</div>
<div class="Section">
<a name="s34"></a><a name="section-7.10.11"></a><p></p>
<h3>Estrogens, Including Oral Contraceptives</h3>
<p class="First">Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</p>
</div>
<div class="Section">
<a name="s35"></a><a name="section-7.10.12"></a><p></p>
<h3>Hepatic Enzyme Inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin)</h3>
<p class="First">Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</p>
</div>
<div class="Section">
<a name="s36"></a><a name="section-7.10.13"></a><p></p>
<h3>Ketoconazole</h3>
<p class="First">Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.</p>
</div>
<div class="Section">
<a name="s37"></a><a name="section-7.10.14"></a><p></p>
<h3>Nonsteroidal Anti-inflammatory Agents (NSAIDS)</h3>
<p class="First">Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.  Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.  The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
</div>
<div class="Section">
<a name="s38"></a><a name="section-7.10.15"></a><p></p>
<h3>Skin Tests</h3>
<p class="First">Corticosteroids may suppress reactions to skin tests.</p>
</div>
<div class="Section">
<a name="s39"></a><a name="section-7.10.16"></a><p></p>
<h3>Vaccines</h3>
<p class="First">Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.  Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.  Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see <a href="#b946fdf2-7f2c-41ee-be5d-a40b55dacc75">WARNINGS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, Vaccination</a> section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s40"></a><a name="section-7.11"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<p class="First">No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s41"></a><a name="section-7.12"></a><p></p>
<h2><span class="Bold">Pregnancy
</span></h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s42"></a><a name="section-7.12.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose.  Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring.  There are no adequate and well-controlled studies in pregnant women.  Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s43"></a><a name="section-7.13"></a><p></p>
<h2><span class="Bold">Nursing Mothers
</span></h2>
<p class="First">Systematically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.  Caution should be exercised when corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s44"></a><a name="section-7.14"></a><p></p>
<h2><span class="Bold">Pediatric Use
</span></h2>
<p class="First">The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations.  Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month of age).  Other indications for pediatric use of corticosteroids, eg, severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.</p>
<p>The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see <a href="#b00467c6-4ca5-4724-9e56-75cba74a5373">ADVERSE REACTIONS</a>).  Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.  Pediatric patients who are treated with corticosteroids by any route, including systematically administered corticosteroids, may experience a decrease in their growth velocity.  This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (ie, cosyntropin stimulation and basal cortisol plasma levels).  Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function.  The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives.  In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s45"></a><a name="section-7.15"></a><p></p>
<h2><span class="Bold">Geriatric Use
</span></h2>
<p class="First">No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and young patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b00467c6-4ca5-4724-9e56-75cba74a5373"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First"><span class="Bold">(listed alphabetically, under each subsection)</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see <a href="#be10f9b4-3ec9-4801-81e4-dd889cc69bc4">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p><span class="Bold">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Bold">Endocrine</span></p>
<p>Decreased carbohydrate and glucose tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, glucosuria, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, increased requirements for insulin or oral hypoglycemic adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients.</p>
<p><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p><a name="b63d5d91-dd53-4c94-9c2f-efb3663c1031"></a><span class="Bold">Gastrointestinal</span></p>
<p>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p><span class="Bold">Metabolic</span></p>
<p>Negative nitrogen balance due to protein catabolism.</p>
<p><a name="b8415b03-c806-4dfc-9047-abc18950a7e2"></a><span class="Bold">Musculoskeletal</span></p>
<p><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, <span class="product-label-link" type="condition" conceptid="4280820" conceptname="Calcinosis">calcinosis</span> (following intra-articular or intralesional use), Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, postinjection flare (following intra-articular use), <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
<p><a name="bbe851ba-8b7d-4d20-871c-5e3d3951fb5d"></a><span class="Bold">Neurologic/Psychiatric</span></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, psychic disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.  <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, and <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> have occurred after intrathecal administration (see <a href="#b9bc56f8-816f-4c6d-a346-5f3ebe099833">WARNINGS, Neurologic</a> section).</p>
<p><span class="Bold">Ophthalmic</span></p>
<p><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> associated with periocular injections.</p>
<p><span class="Bold">Other</span></p>
<p>Abnormal fat deposits, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s46"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> is by supportive and symptomatic therapy.  For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bb68735a-38db-46c7-adcb-b1c3a2337190"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Benzyl alcohol as a preservative has been associated with a fatal “Gasping Syndrome? in premature infants and infants of low birth weight.  Solutions used for further dilution of this product should be preservative-free when used in the neonate, especially the premature infant.  The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9.0 mg per day depending on the specific disease entity being treated.  However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.</p>
<p><span class="Italics">It Should Be Emphasized That Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. </span> After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.  Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment.  In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition.  If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended (see <a href="#b1eece69-2e2b-4a18-92e8-d09614247e42">PRECAUTIONS, Neuro-psychiatric</a> section).</p>
<p>In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated.  The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m<span class="Sup">2</span>bsa/day).</p>
<table frame="void" width="590">
<caption><span> For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids:</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="top">Cortisone, 25</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Triamcinolone, 4</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Hydrocortisone, 20</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Paramethasone, 2</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Prednisolone, 5</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Betamethasone, 0.75</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Prednisone, 5</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Dexamethasone, 0.75 </td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top">Methylprednisolone, 4</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>These dose relationships apply only to oral or intravenous administration of these compounds.  When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</p>
<p>If coadministration of a local anesthetic is desired, Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may be mixed with 1% or 2% lidocaine hydrochloride, using the formulations which do not contain parabens.  Similar local anesthetics may also be used.  Diluents containing methylparaben, propylparaben, phenol, etc., should be avoided, since these compounds may cause flocculation of the steroid.  The required dose of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is first withdrawn from the vial into the syringe.  The local anesthetic is then drawn in, and the syringe shaken briefly.  <span class="Bold">Do not inject local anesthetics into the vial of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension.</span></p>
<div class="Section">
<a name="s47"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">Bursitis</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>, Peritendinitis
</span></h2>
<p class="First">In acute subdeltoid, subacromial, olecranon, and prepatellar <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, one intrabursal injection of 1.0mL Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension can relieve <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and restore full range of movement.  Several intrabursal injections of corticosteroids are usually required in recurrent acute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> and in acute exacerbations of chronic <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>.  Partial relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and some increase in mobility can be expected in both conditions after one or two injections.  Chronic <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> may be treated with reduced dosage once the acute condition is controlled.  In <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span> and <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>, three or four local injections at intervals of 1 to 2 weeks between injections are given in most cases.  Injections should be made into the affected tendon sheaths rather than into the tendons themselves.  In <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglions</span> of joint capsules and tendon sheaths, injection of 0.5 mL directly into the <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> has produced marked reduction in the size of the lesions.</p>
</div>
<div class="Section">
<a name="s48"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span>
</span></h2>
<p class="First">Following intra-articular administration of 0.5 to 2.0 mL of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness, and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> may be experienced.  Duration of relief varies widely in both diseases.  Intra-articular Injection of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is well tolerated in joints and periarticular tissues.  There is virtually no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on injection, and the “secondary flare? that sometimes occurs a few hours after intra-articular injection of corticosteroids has not been reported with Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension.  Using sterile technique, a 20- to 24-gauge needle on an empty syringe is inserted into the synovial cavity and a few drops of synovial fluid are withdrawn to confirm that the needle is in the joint.  The aspirating syringe is replaced by a syringe containing Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension and injection is then made into the joint.</p>
<table frame="void" width="590">
<caption><span>Recommended Doses for Intra-articular Injection</span></caption>
<thead><tr class="First Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold">Size of Joint</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold">Location</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold">Dose (mL)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="top">Very Large</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Hip</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">1.0 - 2.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Large</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Knee, ankle, shoulder</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">1.0</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Medium</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">Elbow, wrist</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.5 - 1.0</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top">Small<br>  (metacarpophalangeal,<br>interphalangeal)<br>(sternoclavicular)</td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle">Hand, chest</td>
<td class="BotruleLruleRruleToprule" align="left" valign="middle">0.25 - 0.5</td>
</tr>
</tbody>
</table>
<p>A portion of the administered dose of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is absorbed systemically following intra-articular injection.  In patients being treated concomitantly with oral or parenteral corticosteroids, especially those receiving large doses, the systemic absorption of the drug should be considered in determining intra-articular dosage.</p>
</div>
<div class="Section">
<a name="s49"></a><a name="section-10.3"></a><p></p>
<h2><span class="Bold">Dermatologic Conditions
</span></h2>
<p class="First">In intralesional treatment, 0.2 mL/cm<span class="Sup">2</span> of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is injected intradermally (not subcutaneously) using a tuberculin syringe with a 25-gauge, 1/2-inch needle.  Care should be taken to deposit a uniform depot of medication intradermally.  A total of no more than 1.0 mL at weekly intervals is recommended.</p>
</div>
<div class="Section">
<a name="s50"></a><a name="section-10.4"></a><p></p>
<h2><span class="Bold">Disorders of the Foot
</span></h2>
<p class="First">A tuberculin syringe with a 25-gauge, 3/4-inch needle is suitable for most injections into the foot.  The following doses are recommended at intervals of 3 days to a week.</p>
<table frame="void" width="590">
<caption><span></span></caption>
<thead><tr class="First Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="Bold">Diagnosis</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">
<span class="Bold">Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension </span><span class="Bold"><br></span><span class="Bold">Dose (mL)</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">Bursitis</span><br>under heloma durum or heloma molle</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.25 - 0.5</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">under calcaneal spur</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.5</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top">over hallux rigidus or digiti quinti varus</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.5</td>
</tr>
<tr>
<td class="BotruleLruleRruleToprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="440822" conceptname="Periostitis">periostitis</span> of cuboid</td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.5</td>
</tr>
<tr class="Last">
<td class="BotruleLruleRruleToprule" align="left" valign="top">Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></td>
<td class="BotruleLruleRruleToprule" align="left" valign="top">0.5 - 1.0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s51"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, 5 mL multiple dose vial; box of one: NDC 0517-0720-01</p>
<p><span class="Bold">SHAKE WELL BEFORE USING.</span></p>
<p><span class="Bold">Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].  Protect from light.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
<p>Revised December 2009</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e8ec904c-dc9b-423b-a953-d9f32bf6b4a8"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">AQUEOUS SOLUTIONS FOR INFILTRATION</span></span></p>
<p><span class="Bold"><span class="Emphasis">AND NERVE BLOCK</span></span></p>
<p><span class="Bold"><span class="Emphasis">Ampul</span></span></p>
<p><span class="Bold"><span class="Emphasis">Plastic Multiple-dose Fliptop Vial</span></span></p>
<p><span class="Bold"><span class="Emphasis">Glass Teartop Vial</span></span></p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="fa3a270a-1a49-4094-992a-6cdfb17b6896"></a><a name="section-13"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of lidocaine hydrochloride in water for injection for parenteral administration in various concentrations with characteristics as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">0.5%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">1%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">1.5%</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">2%</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">mg/mL lidocaine HCl (anhyd.)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">mg/mL sodium chloride</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
</tbody>
</table>
<p>Multiple-dose vials contain 0.1% of methylparaben added as preservative. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH is 6.5 (5.0 to 7.0). See <span class="Italics"><span class="Emphasis"><span class="Bold">HOW SUPPLIED</span></span></span> section for various sizes and strengths.</p>
<p>Lidocaine is a local anesthetic of the amide type.</p>
<p>Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate, a white powder freely soluble in water. The molecular weight is 288.82. It has the following structural formula:</p>
<p><img alt="structural formula lidocaine hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-03.jpg"></p>
<p>The semi-rigid vial used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b32403d3-354b-46cb-ae48-4b5c1b88fa53"></a><a name="section-14"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Mechanism of action:</span></span> Lidocaine stabilizes the        neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction        of impulses, thereby effecting local anesthetic action.</p>
<p><span class="Bold"><span class="Emphasis">Hemodynamics:</span></span> Excessive blood levels may cause        changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance, and mean arterial pressure. With        central neural blockade these changes may be attributable to block of autonomic fibers, a        direct depressant effect of the local anesthetic agent on various components of the        cardiovascular system and/or the beta-adrenergic receptor stimulating action of epinephrine        when present. The net effect is normally a modest <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> when the recommended dosages        are not exceeded.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics and metabolism:</span></span> Information        derived from diverse formulations, concentrations and usages reveals that lidocaine is        completely absorbed following parenteral administration, its rate of absorption depending,        for example, upon various factors such as the site of administration and the presence or        absence of a vasoconstrictor agent. Except for intravascular administration, the highest        blood levels are obtained following intercostal nerve block and the lowest after subcutaneous        administration.</p>
<p>The plasma binding of lidocaine is dependent on drug concentration, and the        fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of        free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent        on the plasma concentration of the alpha-1-acid glycoprotein.</p>
<p>Lidocaine crosses the blood-brain and placental barriers, presumably by passive        diffusion.</p>
<p>Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug        are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring        hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major        pathway of biotransformation, yields the metabolites monoethylglycinexylidide and        glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar        to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is        excreted in the form of various metabolites, and less than 10% is excreted unchanged. The        primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.</p>
<p>The elimination half-life of lidocaine following an intravenous bolus injection is        typically 1.5 to 2.0 hours. Because of the rapid rate at which lidocaine is metabolized, any        condition that affects liver function may alter lidocaine kinetics. The half-life may be        prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not        affect lidocaine kinetics but may increase the accumulation of metabolites.</p>
<p>Factors such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and the use of CNS stimulants and depressants affect the        CNS levels of lidocaine required to produce overt systemic effects. Objective adverse        manifestations become increasingly apparent with increasing venous plasma levels above 6.0        mcg free base per mL. In the rhesus monkey arterial blood levels of 18-21 mcg/mL have been        shown to be threshold for convulsive activity.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a3d734fd-fe42-4985-a278-b6c385b13cb6"></a><a name="section-15"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is indicated for production of local or        regional anesthesia by infiltration techniques such as percutaneous injection and intravenous        regional anesthesia by peripheral nerve block techniques such as brachial plexus and        intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when        the accepted procedures for these techniques as described in standard textbooks are       observed.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="d8759c45-f178-4a64-af1d-38662779adbf"></a><a name="section-16"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lidocaine is contraindicated in patients with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>        to local anesthetics of the amide type.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b5ad8057-f48b-482f-b8f2-ac7b994ea894"></a><a name="section-17"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LIDOCAINE HYDROCHLORIDE INJECTION, FOR INFILTRATION AND NERVE BLOCK, SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE <span class="Bold"><span class="Emphasis">IMMEDIATE</span></span> AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT, AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (See also <span class="Bold"><span class="Emphasis"><span class="Italics">ADVERSE REACTIONS</span></span></span> and <span class="Bold"><span class="Emphasis"><span class="Italics">PRECAUTIONS</span></span></span>). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">ACIDOSIS</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span> AND, POSSIBLY, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
<p>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving such infusions. The majority of reported cases of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have involved the shoulder joint; cases of gleno-humeral <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span>; patients who experienced <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.</p>
<p>To avoid intravascular injection, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be performed before the local anesthetic solution is injected. The needle must be repositioned until no return of blood can be elicited by <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p>Local anesthetic solutions containing antimicrobial preservatives (e.g., methylparaben) should not be used for epidural or spinal anesthesia because the safety of these agents has not been established with regard to intrathecal injection, either intentional or accidental.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="aedfc012-2bf3-43b5-a741-a790b2f48fdd"></a><a name="section-18"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="b9ac3889-dad8-4530-837d-acb5432729c6"></a><a name="section-18.1"></a><p></p>
<h2>General:</h2>
<p class="First">The safety and effectiveness of lidocaine depend on proper dosage, correct          technique, adequate precautions, and readiness for emergencies. Standard textbooks should          be consulted for specific techniques and precautions for various regional anesthetic          procedures.</p>
<p>Resuscitative equipment, oxygen, and other resuscitative drugs should be          available for immediate use. (See <span class="Bold"><span class="Emphasis"><span class="Italics">WARNINGS</span></span></span> and <span class="Bold"><span class="Emphasis"><span class="Italics">ADVERSE REACTIONS</span></span></span>). The lowest dosage that results in effective anesthesia should be used to avoid          high plasma levels and serious adverse effects. Syringe <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> should also be          performed before and during each supplemental injection when using indwelling catheter          techniques. During the administration of epidural anesthesia, it is recommended that a test          dose be administered initially and that the patient be monitored for central nervous system          toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal          administration before proceeding. When clinical conditions permit, consideration should be          given to employing local anesthetic solutions that contain epinephrine for the test dose          because circulatory changes compatible with epinephrine may also serve as a warning sign of          unintended intravascular injection. An intravascular injection is still possible even if          <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> for blood are negative. Repeated doses of lidocaine may cause significant          increases in blood levels with each repeated dose because of slow accumulation of the drug          or its metabolites. Tolerance to elevated blood levels varies with the status of the          patient. Debilitated, elderly patients, acutely ill patients and children should be given          reduced doses commensurate with their age and physical condition. Lidocaine should also be          used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Lumbar and caudal epidural          anesthesia should be used with extreme caution in persons with the following conditions:          existing neurological disease, spinal deformities, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> and severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Local anesthetic solutions containing a vasoconstrictor should be used cautiously          and in carefully circumscribed quantities in areas of the body supplied by end arteries or          having otherwise compromised blood supply. Patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> and          those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response.          Ischemic injury or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> may result. Preparations containing a vasoconstrictor should be          used with caution in patients during or following the administration of potent general          anesthetic agents, since <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur under such conditions.</p>
<p>Careful and constant monitoring of cardiovascular and respiratory (adequacy of          ventilation) vital signs and the patient’s state of consciousness should be          accomplished after each local anesthetic injection. It should be kept in mind at such times          that <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or          <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Since amide-type local anesthetics are metabolized by the liver, lidocaine should          be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients with severe hepatic          disease, because of their inability to metabolize local anesthetics normally, are at          greater risk of developing toxic plasma concentrations. Lidocaine should also be used with          caution in patients with impaired cardiovascular function since they may be less able to          compensate for functional changes associated with the prolongation of A-V conduction          produced by these drugs. Many drugs used during the conduct of anesthesia are considered          potential triggering agents for familial <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. Since it is not known          whether amide-type local anesthetics may trigger this reaction and since the need for          supplemental general anesthesia cannot be predicted in advance, it is suggested that a          standard protocol for the management of <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span> should be available. Early          unexplained signs of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>          may precede temperature elevation. Successful outcome is dependent on early diagnosis,          prompt discontinuance of the suspect triggering agent(s) and institution of treatment,          including oxygen therapy, indicated supportive measures and dantrolene (consult dantrolene          sodium intravenous package insert before using).</p>
<p>Proper tourniquet technique, as described in publications and standard textbooks,          is essential in the performance of intravenous regional anesthesia. Solutions containing          epinephrine or other vasoconstrictors should not be used for this technique.</p>
<p>Lidocaine should be used with caution in persons with known drug sensitivities.          Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine,          etc.) have not shown cross sensitivity to lidocaine.</p>
<p><span class="Bold"><span class="Emphasis">Use in the Head and Neck Area:</span></span> Small doses of          local anesthetics injected into the head and neck area, including retrobulbar, dental and          stellate <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blocks, may produce adverse reactions similar to systemic toxicity seen          with unintentional intravascular injections of larger doses. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,          <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> and cardiovascular stimulation or          <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have been reported. These reactions may be due to intra-arterial injections of          the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving          these blocks should have their circulation and respiration monitored and be constantly          observed. Resuscitative equipment and personnel for treating adverse reactions should be          immediately available. Dosage recommendations should not be exceeded. (See <span class="Bold"><span class="Emphasis"><span class="Italics">DOSAGE AND ADMINISTRATION</span></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="d02dbd9c-b14a-41e7-97a7-75a02813ea68"></a><a name="section-18.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">When appropriate, patients should be informed in advance that they may experience          temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and motor activity, usually in the lower half of the body          following proper administration of epidural anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ed06d08b-cbf7-47f7-a3a9-9def2e7b70f7"></a><a name="section-18.3"></a><p></p>
<h2>Clinically Significant Drug Interactions:</h2>
<p class="First">The administration of local anesthetic solutions containing epinephrine or          norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic          antidepressants may produce severe prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of          epinephrine.</p>
<p>Concurrent use of these agents should generally be avoided. In situations when          concurrent therapy is necessary, careful patient monitoring is essential.</p>
<p>Concurrent administration of vasopressor drugs (for the treatment of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>          related to obstetric blocks) and ergot-type oxytoxic drugs may cause severe persistent          <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="cb911dd0-55aa-4d36-b19d-40c2a26d03ae"></a><a name="section-18.4"></a><p></p>
<h2>Drug Laboratory Test Interactions:</h2>
<p class="First">The intramuscular injection of lidocaine may result in an increase in creatine          phosphokinase levels. Thus, the use of this enzyme determination without isoenzyme          separation as a diagnostic test for the presence of <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> may be          compromised by the intramuscular injection of lidocaine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="d0465307-215b-42f9-bbd4-597bcb5a7015"></a><a name="section-18.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic          potential or the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="e6593aba-31ea-4e41-9be9-dcb82a6f96c5"></a><a name="section-18.6"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Teratogenic Effects. Pregnancy Category B.</span></span>          Reproduction studies have been performed in rats at doses up to 6.6 times the human dose          and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however,          no adequate and well-controlled studies in pregnant women. Animal reproduction studies are          not always predictive of human response. General consideration should be given to this fact          before administering lidocaine to women of childbearing potential, especially during early          pregnancy when maximum organogenesis takes place.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ad368f77-241c-40e8-a2d9-f77bb055cefa"></a><a name="section-18.7"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">Local anesthetics rapidly cross the placenta and when used for epidural,          paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal,          fetal and neonatal toxicity (See <span class="Bold"><span class="Emphasis"><span class="Italics">CLINICAL PHARMACOLOGY</span></span></span>—<span class="Bold"><span class="Emphasis">Pharmacokinetics</span></span>). The potential          for toxicity depends upon the procedure performed, the type and amount of drug used, and          the technique of drug administration. Adverse reactions in the parturient, fetus and          neonate involve alterations of the central nervous system peripheral vascular tone and          cardiac function.</p>
<p>Maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has resulted from regional anesthesia. Local anesthetics          produce vasodilation by blocking sympathetic nerves. Elevating the patient’s          legs and positioning her on her left side will help prevent decreases in blood pressure.          The fetal heart rate also should be monitored continuously, and electronic fetal monitoring          is highly advisable.</p>
<p>Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of          parturition through changes in uterine contractility or maternal expulsive efforts. In one          study, paracervical block anesthesia was associated with a decrease in the mean duration of          first stage labor and facilitation of cervical dilation. However, spinal and epidural          anesthesia have also been reported to prolong the second stage of labor by removing the          parturient’s reflex urge to bear down or by interfering with motor function. The          use of obstetrical anesthesia may increase the need for forceps assistance.</p>
<p>The use of some local anesthetic drug products during labor and delivery may be          followed by diminished muscle strength and tone for the first day or two of life. The          long-term significance of these observations is unknown. <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">Fetal bradycardia</span> may occur in 20          to 30 percent of patients receiving paracervical nerve block anesthesia with the amide-type          local anesthetics and may be associated with <span class="product-label-link" type="condition" conceptid="4344632" conceptname="Fetal acidosis">fetal acidosis</span>. Fetal heart rate should always          be monitored during paracervical anesthesia. The physician should weigh the possible          advantages against risks when considering paracervical block in <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, toxemia of          pregnancy and <span class="product-label-link" type="condition" conceptid="73268" conceptname="Fetal distress affecting management of mother">fetal distress</span>. Careful adherence to recommended dosage is of the utmost          importance in obstetrical paracervical block. Failure to achieve adequate <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> with          recommended doses should arouse suspicion of intravascular or fetal intracranial injection.          Cases compatible with unintended fetal intracranial injection of local anesthetic solution          have been reported following intended paracervical or pudendal block or both. Babies so          affected present with unexplained neonatal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> at birth, which correlates with high          local anesthetic serum levels, and often manifest <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> within six hours. Prompt use of          supportive measures combined with forced urinary excretion of the local anesthetic has been          used successfully to manage this complication.</p>
<p>Case reports of maternal <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> following use of          some local anesthetics for paracervical block in early pregnancy (as anesthesia for          elective abortion) suggest that systemic absorption under these circumstances may be rapid.          The recommended maximum dose of each drug should not be exceeded. Injection should be made          slowly and with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Allow a 5-minute interval between sides.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="a4698bba-cb8b-424e-aaa6-29a88dbc5b92"></a><a name="section-18.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs          are excreted in human milk, caution should be exercised when lidocaine is administered to a          nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="d39ff672-1b87-4753-95e4-181b82409016"></a><a name="section-18.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Dosages in pediatric patients should be reduced, commensurate with age, body          weight and physical condition. See <span class="Bold"><span class="Emphasis"><span class="Italics">DOSAGE AND ADMINISTRATION</span></span></span><span class="Bold"><span class="Emphasis"><span class="Italics">.</span></span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b5d71aee-9fed-4b73-ac72-46e23cb6aa08"></a><a name="section-19"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Systemic:</span></span> Adverse experiences following the        administration of lidocaine are similar in nature to those observed with other amide local        anesthetic agents. These adverse experiences are, in general, dose-related and may result        from high plasma levels caused by excessive dosage, rapid absorption or inadvertent        intravascular injection, or may result from a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy or diminished        tolerance on the part of the patient. Serious adverse experiences are generally systemic in        nature. The following types are those most commonly reported:</p>
<p><span class="Bold"><span class="Emphasis">Central Nervous System:</span></span> CNS manifestations are        excitatory and/or depressant and may be characterized by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>,        <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, blurred or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>,        <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensations of heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,        <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and arrest. The excitatory manifestations may be very        brief or may not occur at all, in which case the first manifestation of toxicity may be        <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> following the administration of lidocaine is usually an early sign of a        high blood level of the drug and may occur as a consequence of rapid absorption.</p>
<p><span class="Bold"><span class="Emphasis">Cardiovascular System:</span></span> Cardiovascular        manifestations are usually depressant and are characterized by <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and        <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, which may lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p><span class="Bold"><span class="Emphasis">Allergic:</span></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> are characterized        by cutaneous lesions, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may        occur as a result of sensitivity either to local anesthetic agents or to the methylparaben        used as a preservative in multiple dose vials. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> as a result of sensitivity        to lidocaine are extremely rare and, if they occur, should be managed by conventional means.        The detection of sensitivity by skin testing is of doubtful value.</p>
<p><span class="Bold"><span class="Emphasis">Neurologic:</span></span> The incidences of adverse reactions        associated with the use of local anesthetics may be related to the total dose of local        anesthetic administered and are also dependent upon the particular drug used, the route of        administration and the physical status of the patient. In a prospective review of 10,440        patients who received lidocaine for spinal anesthesia, the incidences of adverse reactions        were reported to be about 3 percent each for positional <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>;        2 percent for <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>; and less than 1 percent each for peripheral nerve symptoms, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,        respiratory inadequacy and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>. Many of these observations may be related to local        anesthetic techniques, with or without a contribution from the local anesthetic.</p>
<p>In the practice of caudal or lumbar epidural block, occasional unintentional        penetration of the subarachnoid space by the catheter may occur. Subsequent adverse effects        may depend partially on the amount of drug administered subdurally.</p>
<p>These may include spinal block of varying magnitude (including total spinal block),        <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> secondary to spinal block, loss of bladder and bowel control, and loss of        perineal sensation and sexual function. Persistent motor, sensory and/or autonomic (sphincter        control) deficit of some lower spinal segments with slow recovery (several months) or        incomplete recovery have been reported in rare instances when caudal or lumbar epidural block        has been attempted. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Backache</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have also been noted following use of these        anesthetic procedures.</p>
<p>There have been reported cases of permanent injury to extraocular muscles requiring        surgical repair following retrobulbar administration.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="d514f782-068f-4d96-a0ca-7d54f8bbd0b3"></a><a name="section-20"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see<span class="Bold"><span class="Emphasis"><span class="Italics"> ADVERSE REACTIONS, </span></span></span><span class="Bold"><span class="Emphasis"><span class="Italics">WARNINGS</span></span></span> and <span class="Bold"><span class="Emphasis"><span class="Italics">PRECAUTIONS</span></span></span>).</p>
<p><span class="Bold"><span class="Emphasis">Management of Local Anesthetic Emergencies:</span></span> The first consideration is prevention, best accomplished by careful monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.</p>
<p>The first step in the management of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, as well as underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> sometimes depress the circulation when administered intravenously. Should <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).</p>
<p>If not treated immediately, both <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can result in <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if ventilatory support is not instituted. If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur standard cardiopulmonary resuscitative measures should be instituted.</p>
<p>Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated.</p>
<p>Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.</p>
<p>The oral LD<span class="Sub">50</span> of lidocaine HCl in non-fasted female rats is 459 (346−773) mg/kg (as the salt) and 214 (159−324) mg/kg (as the salt) in fasted female rats.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f2b072b9-3c6f-49e9-b937-29d8f6f311ed"></a><a name="section-21"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of Lidocaine Hydrochloride Injection, USP for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required only solutions containing epinephrine should be used, except in those cases where vasopressor drugs may be contraindicated.</p>
<p>There have been adverse event reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  Lidocaine is not approved for this use (see <span class="Bold"><span class="Emphasis"><span class="Italics">WARNINGS</span></span></span> and <span class="Bold"><span class="Emphasis"><span class="Italics">DOSAGE AND ADMINISTRATION</span></span></span>).</p>
<p>These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for elderly and debilitated patients and patients with cardiac and/or liver disease.</p>
<p>The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of Lidocaine Hydrochloride Injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of Lidocaine Hydrochloride Injection may result in a more profound <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> when used in epidural anesthesia. Although the incidence of side effects with lidocaine is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.</p>
<p>For intravenous regional anesthesia, only the 50 mL single-dose vial containing 0.5% Lidocaine Hydrochloride Injection, USP should be used.</p>
<p><span class="Bold"><span class="Emphasis">Epidural Anesthesia</span></span></p>
<p>For epidural anesthesia, only the following <span class="Underline"><span class="Emphasis">available</span></span> specific products of Lidocaine Hydrochloride Injection by Hospira are recommended:</p>
<p>1%. . . . . . . . . . . . . . . . . . . . 30 mL single-dose teartop vials</p>
<p>1.5%. . . . . . . . . . . . . . . . . . . . . . . 20 mL single-dose ampuls</p>
<p>2%. . . . . . . . . . . . . . . . . . . . . . . . . 10 mL single-dose ampuls</p>
<p>Although these solutions are intended specifically for epidural anesthesia, they may also be used for infiltration and peripheral nerve block provided they are employed as single dose units. These solutions contain no bacteriostatic agent. In epidural anesthesia, the dosage varies with the number of dermatomes to be anesthetized (generally 2−3 mL of the indicated concentration per dermatome).</p>
<p><span class="Bold"><span class="Emphasis">Caudal and Lumbar Epidural Block:</span></span> As a precaution against the adverse experiences sometimes observed following unintentional penetration of the subarachnoid space, a test dose such as 2−3 mL of 1.5% lidocaine hydrochloride should be administered at least 5 minutes prior to injecting the total volume required for a lumbar or caudal epidural block. The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose (10−15 mcg have been suggested), may serve as a warning of unintentional intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient "epinephrine response" within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure. Adequate time should be allowed for onset of anesthesia after administration of each test dose. The rapid injection of a large volume of Lidocaine Hydrochloride Injection through the catheter should be avoided, and, when feasible, fractional doses should be administered.</p>
<p>In the event of the known injection of a large volume of local anesthetic solutions into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.</p>
<p><span class="Bold"><span class="Emphasis">Maximum Recommended Dosages</span></span></p>
<p><span class="Bold"><span class="Emphasis">NOTE: The products accompanying this insert do not contain epinephrine.</span></span></p>
<p><span class="Bold"><span class="Emphasis">Adults:</span></span> For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight and in general it is recommended that the maximum total dose not exceed 500 mg. When used without epinephrine, the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight and in general it is recommended that the maximum total dose does not exceed 300 mg. For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes. When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.</p>
<p>The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total. One-half of the total dose is usually administered to each side. Inject slowly five minutes between sides. (See also discussion of paracervical block in <span class="Bold"><span class="Emphasis"><span class="Italics">PRECAUTIONS</span></span></span>).</p>
<p>For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.</p>
<p><span class="Bold"><span class="Emphasis">Children:</span></span> It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and normal body development, the maximum dose is determined by the child’s age and weight. For example, in a child of 5 years weighing 50 lbs., the dose of lidocaine HCl should not exceed 75 — 100 mg (1.5 — 2 mg/lb). The use of even more dilute solutions (i.e., 0.25 — 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children.</p>
<p>In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times. In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions that are discolored and/or contain particulate matter should not be used. </p>
<table>
<colgroup><col align="left"></colgroup>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Table 1</span></span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Recommended Dosages of Lidocaine Hydrochloride Injection, USP for Various Anesthetic</span></span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Procedures in Normal Healthy Adults</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Lidocaine Hydrochloride Injection, USP (without Epinephrine)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Procedure</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Conc. (%)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Vol. (mL)</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Total Dose (mg)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Italics">Infiltration</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Percutaneous</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5 or 1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1−60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Intravenous Regional</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10−60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Italics">Peripheral Nerve Blocks, e.g.</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Brachial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15−20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Dental</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1−5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20−100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Intercostal</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Paravertebral</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3−5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30−50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Pudendal (each side)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Paracervical</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">(each side)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Italics">Sympathetic Nerve Blocks, e.g.</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Cervical (stellate <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Lumbar</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5−10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50−100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis"><span class="Italics">Central Neural Blocks</span></span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Epidural*</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Thoracic</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20−30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Lumbar</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25−30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Anesthesia</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15−20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10−15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Caudal</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20−30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Surgical Anesthesia</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15−20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">225−300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="4" valign="top"><p class="First">*Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome).</p></td></tr>
</tbody>
</table>
<p>THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE. OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.</p>
<p><span class="Bold"><span class="Emphasis">Sterilization, Storage and Technical Procedures:</span></span> Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection as they have been related to incidence of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. When chemical disinfection of multi-dose vials is desired, either isopropyl alcohol (91%) or 70% ethyl alcohol is recommended. Many commercially available brands of rubbing alcohol, as well as solutions of ethyl alcohol not of USP grade, contain denaturants which are injurious to rubber and, therefore, are not to be used. It is recommended that chemical disinfection be accomplished by wiping the vial stopper thoroughly with cotton or gauze that has been moistened with the recommended alcohol just prior to use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="b800de14-94bc-451a-aeff-7d3a3e536588"></a><a name="section-22"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Lidocaine Hydrochloride Injection, USP is supplied as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Container</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Size</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Total (mg)</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Single-dose:</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4278-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL (bulk – 400 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-05</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL (bulk – 400 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-32</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-62</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL (bulk – 800 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4713-65</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5 mL (bulk – 800 units)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4279-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4270-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Sterile Glass Teartop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4776-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5% (15 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4056-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Sterile Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1.5% (15 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">300</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4282-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4282-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Glass Ampul</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Multiple-dose:</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4275-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0.5% (5 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">250</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4276-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4276-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% (10 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">500</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4277-01</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">400</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">0409-4277-02</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Plastic Fliptop Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% (20 mg/mL)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">50 mL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1000</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Single-dose products are preservative-free.</p>
<p>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Lidocaine Hydrochloride Injection, USP solutions packaged in ampuls and glass teartop vials may be autoclaved one time only. Autoclave at 15 pounds pressure, 121°C (250°F) for 15 minutes. <span class="Bold"><span class="Emphasis">DO NOT AUTOCLAVE PRODUCT IN PLASTIC VIALS. </span></span></p>
<p>Revised: February, 2010</p>
<p>Printed in USA                            EN-2421</p>
<p>Hospira, Inc., Lake Forest, IL 60045 USA</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e9161557-6ce6-4cd2-96ec-a4a422f03e71"></a><a name="section-23"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Marcaine™</span></span></p>
<p>Bupivacaine Hydrochloride Injection, USP</p>
<p><span class="Bold"><span class="Emphasis">Marcaine™</span></span></p>
<p>With Epinephrine 1:200,000 (as bitartrate)</p>
<p>Bupivacaine Hydrochloride and Epinephrine Injection, USP                 Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="be34ff3f-5e41-45bb-b4c0-0e44abb66dcb"></a><a name="section-24"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Bupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-<span class="Italics"><span class="Emphasis">N</span></span>-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:</p>
<p><img alt="structural formula bupivacaine hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-04.jpg"></p>
<br><p>Epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl] benzyl alcohol. It has the following structural formula:</p>
<p><img alt="structural formula epinephrine" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-05.jpg"></p>
<br><p>MARCAINE is available in sterile isotonic solutions with and without epinephrine (as bitartrate) 1:200,000 for injection via local infiltration, peripheral nerve block, and caudal and lumbar epidural blocks. Solutions of MARCAINE may be autoclaved if they do not contain epinephrine. Solutions are clear and colorless.</p>
<p>Bupivacaine is related chemically and pharmacologically to the aminoacyl local anesthetics. It is a homologue of mepivacaine and is chemically related to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage.</p>
<p><span class="Italics"><span class="Emphasis">MARCAINE</span></span> — Sterile isotonic solutions containing sodium chloride. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 4 and 6.5 with sodium hydroxide or hydrochloric acid.</p>
<p><span class="Italics"><span class="Emphasis">MARCAINE </span></span><span class="Italics"><span class="Emphasis">with epinephrine 1:200,000</span></span> (as bitartrate)—Sterile isotonic solutions containing sodium chloride. Each mL contains bupivacaine hydrochloride and 0.0091 mg epinephrine bitartrate, with 0.5 mg sodium metabisulfite, 0.001 mL monothioglycerol, and 2 mg ascorbic acid as antioxidants, 0.0017 mL 60% sodium lactate buffer, and 0.1 mg edetate calcium disodium as stabilizer. In multiple-dose vials, each mL also contains 1 mg methylparaben as antiseptic preservative. The pH of these solutions is adjusted to between 3.4 and 4.5 with sodium hydroxide or hydrochloric acid. The specific gravity of MARCAINE 0.5% with epinephrine 1:200,000 (as bitartrate) at 25°C is 1.008 and at 37°C is 1.008.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e314cf85-3b8e-49f0-aaf8-b4be4be44480"></a><a name="section-25"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Local anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, (2) temperature, (3) touch,  (4) proprioception, and (5) skeletal muscle tone.</p>
<p>Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems (CNS). At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, refractoriness, contractility, and peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are minimal. However, toxic blood concentrations depress cardiac conduction and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure. Recent clinical reports and animal research suggest that these cardiovascular changes are more likely to occur after unintended intravascular injection of bupivacaine. Therefore, incremental dosing is necessary.</p>
<p>Following systemic absorption, local anesthetics can produce central nervous system stimulation, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or both. Apparent central stimulation is manifested as <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span> progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, followed by <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> progressing ultimately to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. However, the local anesthetics have a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited state.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics:</span></span> The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution. A dilute concentration of epinephrine (1:200,000 or 5 mcg/mL) usually reduces the rate of absorption and peak plasma concentration of MARCAINE, permitting the use of moderately larger total doses and sometimes prolonging the duration of action. </p>
<p>The onset of action with MARCAINE is rapid and anesthesia is long lasting. The duration of anesthesia is significantly longer with MARCAINE than with any other commonly used local anesthetic. It has also been noted that there is a period of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> that persists after the return of sensation, during which time the need for strong analgesics is reduced.</p>
<p>The onset of action following dental injections is usually 2 to 10 minutes and anesthesia may last two or three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000.</p>
<p>Local anesthetics are bound to plasma proteins in varying degrees. Generally, the lower the plasma concentration of drug the higher the percentage of drug bound to plasma proteins.</p>
<p>Local anesthetics appear to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility. Fetal/ maternal ratios of local anesthetics appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. MARCAINE with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation.</p>
<p>Depending upon the route of administration, local anesthetics are distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.</p>
<p>Pharmacokinetic studies on the plasma profile of MARCAINE after direct intravenous injection suggest a three-compartment open model. The first compartment is represented by the rapid intravascular distribution of the drug. The second compartment represents the equilibration of the drug throughout the highly perfused organs such as the brain, myocardium, lungs, kidneys, and liver. The third compartment represents an equilibration of the drug with poorly perfused tissues, such as muscle and fat. The elimination of drug from tissue distribution depends largely upon the ability of binding sites in the circulation to carry it to the liver where it is metabolized.</p>
<p>After injection of MARCAINE for caudal, epidural, or peripheral nerve block in man, peak levels of bupivacaine in the blood are reached in 30 to 45 minutes, followed by a decline to insignificant levels during the next three to six hours.</p>
<p>Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, addition of epinephrine, factors affecting urinary pH, renal blood flow, the route of drug administration, and the age of the patient. The half-life of MARCAINE in adults is 2.7 hours and in neonates 8.1 hours. </p>
<p>In clinical studies, elderly patients reached the maximal spread of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and maximal motor blockade more rapidly than younger patients. Elderly patients also exhibited higher peak plasma concentrations following administration of this product. The total plasma clearance was decreased in these patients.</p>
<p>Amide-type local anesthetics such as MARCAINE are metabolized primarily in the liver via conjugation with glucuronic acid. Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, especially those with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, may be more susceptible to the potential toxicities of the amide-type local anesthetics. Pipecoloxylidine is the major metabolite of MARCAINE.</p>
<p>The kidney is the main excretory organ for most local anesthetics and their metabolites. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Only 6% of bupivacaine is excreted unchanged in the urine.</p>
<p>When administered in recommended doses and concentrations, MARCAINE does not ordinarily produce irritation or tissue damage and does not cause <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="f88a868c-85a4-4fe9-9ace-bac560477fc1"></a><a name="section-26"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MARCAINE is indicated for the production of local or regional anesthesia or <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See <span class="Bold"><span class="Emphasis">WARNINGS</span></span>.)</p>
<p>Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of MARCAINE in these patients.</p>
<p>MARCAINE is not recommended for intravenous regional anesthesia (Bier Block). See <span class="Bold"><span class="Emphasis">WARNINGS</span></span>.</p>
<p>The routes of administration and indicated MARCAINE concentrations are:</p>
<p>∙ local infiltration                                                                                 0.25%</p>
<p>∙ peripheral nerve block                                                                      0.25% and 0.5%</p>
<p>∙ retrobulbar block                                                                              0.75%</p>
<p>∙ sympathetic block                                                                             0.25%</p>
<p>∙ lumbar epidural                                                                                 0.25%, 0.5%, and 0.75%</p>
<p>                                                                                                          (0.75% not for obstetrical anesthesia)</p>
<p>∙ caudal                                                                                               0.25% and 0.5%</p>
<p>∙ epidural test dose                                                                              0.5% with epinephrine 1:200,000</p>
<p>∙ dental blocks                                                                                     0.5% with epinephrine 1:200,000</p>
<p>(See <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span> for additional information.)</p>
<p>Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of MARCAINE.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="c9ed79d4-4545-4eb8-9b8e-23e6b359de5e"></a><a name="section-27"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">MARCAINE is contraindicated in obstetrical paracervical block anesthesia. Its use in this technique has resulted in <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>MARCAINE is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it or to any local anesthetic agent of the amide-type or to other components of MARCAINE solutions.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b053ba44-3a15-4401-96c4-fcc362a74ace"></a><a name="section-28"></a><p></p>
<h1>WARNINGS</h1>
<table><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"><span class="Emphasis">THE 0.75% CONCENTRATION OF MARCAINE IS NOT RECOMMENDED FOR OBSTETRICAL ANESTHESIA. THERE HAVE BEEN REPORTS OF <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span> WITH DIFFICULT RESUSCITATION OR <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> DURING USE OF MARCAINE FOR EPIDURAL ANESTHESIA IN OBSTETRICAL PATIENTS. IN MOST CASES, THIS HAS FOLLOWED USE OF THE 0.75% CONCENTRATION. RESUSCITATION HAS BEEN DIFFICULT OR IMPOSSIBLE DESPITE APPARENTLY ADEQUATE PREPARATION AND APPROPRIATE MANAGEMENT. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span> HAS OCCURRED AFTER <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">CONVULSIONS</span> RESULTING FROM SYSTEMIC TOXICITY, PRESUMABLY FOLLOWING UNINTENTIONAL INTRAVASCULAR INJECTION. THE 0.75% CONCENTRATION SHOULD BE RESERVED FOR SURGICAL PROCEDURES WHERE A HIGH DEGREE OF <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">MUSCLE RELAXATION</span> AND PROLONGED EFFECT ARE NECESSARY.</span></span></p></td></tr></tbody></table>
<p class="First">LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE <span class="Bold"><span class="Emphasis">IMMEDIATE</span></span> AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES. (See also <span class="Bold"><span class="Emphasis">ADVERSE REACTIONS</span></span>, <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>, and <span class="Bold"><span class="Emphasis">OVERDOSAGE</span></span>.) DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE, AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">ACIDOSIS</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span> AND, POSSIBLY, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
<p>Local anesthetic solutions containing antimicrobial preservatives, i.e., those supplied in multiple-dose vials, should not be used for epidural or caudal anesthesia because safety has not been established with regard to intrathecal injection, either intentionally or unintentionally, of such preservatives.</p>
<p>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving such infusions. The majority of reported cases of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have involved the shoulder joint; cases of gleno-humeral <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and loss of motion can be variable, but may begin as early as the 2nd month after surgery. Currently, there is no effective treatment for <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span>; patients who experienced <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.</p>
<p>It is essential that <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. However, a negative <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> does not ensure against an intravascular or subarachnoid injection.</p>
<p>MARCAINE with epinephrine 1:200,000 or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may occur. Likewise, solutions of MARCAINE containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamineoxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may result.</p>
<p>Until further experience is gained in pediatric patients younger than 12 years, administration of MARCAINE in this age group is not recommended.</p>
<p>Mixing or the prior or intercurrent use of any other local anesthetic with MARCAINE cannot be recommended because of insufficient data on the clinical use of such mixtures.</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> during the use of MARCAINE for intravenous regional anesthesia (Bier Block). Information on safe dosages and techniques of administration of MARCAINE in this procedure is lacking. Therefore, MARCAINE is not recommended for use in this technique.</p>
<p><span class="Italics"><span class="Emphasis">MARCAINE with epinephrine 1:200,000</span></span> contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people. Single-dose ampuls and single-dose vials of <span class="Italics"><span class="Emphasis">MARCAINE</span></span> without epinephrine do not contain sodium metabisulfite.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="aea192a7-318d-4ebb-bbfa-30afb5b235cd"></a><a name="section-29"></a><p></p>
<h1>PRECAUTIONS</h1>
<br><div class="Section" data-sectionCode="34072-9">
<a name="cff13a0d-7ecd-4bf7-b99d-80c9ef43c8f9"></a><a name="section-29.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">General:</span></span> The safety and effectiveness of local anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. (See <span class="Bold"><span class="Emphasis">WARNINGS</span></span>, <span class="Bold"><span class="Emphasis">ADVERSE REACTIONS</span></span>, and <span class="Bold"><span class="Emphasis">OVERDOSAGE</span></span>.) During major regional nerve blocks, the patient should have IV fluids running via an indwelling catheter to assure a functioning intravenous pathway. The lowest dosage of local anesthetic that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.</p>
<br><p><span class="Bold"><span class="Emphasis">Epidural Anesthesia:</span></span> During epidural administration of MARCAINE, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Injections should be made slowly, with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> before and during the injection to avoid intravascular injection. Syringe <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> should also be performed before and during each supplemental injection in continuous (intermittent) catheter techniques. An intravascular injection is still possible even if <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span> for blood are negative.</p>
<p>During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and the effects monitored before the full dose is given. When using a “continuous? catheter technique, test doses should be given prior to both the original and all reinforcing doses, because plastic tubing in the epidural space can migrate into a blood vessel or through the dura. When clinical conditions permit, the test dose should contain epinephrine (10 mcg to 15 mcg has been suggested) to serve as a warning of unintended intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient “epinephrine response? within 45 seconds, consisting of an increase in heart rate and/or systolic blood pressure, circumoral <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart rate should be monitored for a heart rate increase. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a transient rise in systolic blood pressure. The test dose should also contain 10 mg to 15 mg of MARCAINE or an equivalent amount of another local anesthetic to detect an unintended intrathecal administration. This will be evidenced within a few minutes by signs of spinal block (e.g., decreased sensation of the buttocks, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span> of the legs, or, in the sedated patient, absent knee jerk). The Test Dose formulation of MARCAINE contains 15 mg of bupivacaine and 15 mcg of epinephrine in a volume of 3 mL. An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or epinephrine-induced cardiovascular effects.</p>
<p>Injection of repeated doses of local anesthetics may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients and acutely ill patients should be given reduced doses commensurate with their age and physical status. Local anesthetics should also be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or heartblock.</p>
<p>Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after each local anesthetic injection. It should be kept in mind at such times that <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the mouth and lips, metallic taste, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis. Patients with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> may result.</p>
<p>Because amide-local anesthetics such as MARCAINE are metabolized by the liver, these drugs, especially repeat doses, should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. Local anesthetics should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.</p>
<p>Serious dose-related <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur if preparations containing a vasoconstrictor such as epinephrine are employed in patients during or following the administration of potent inhalation anesthetics. In deciding whether to use these products concurrently in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.</p>
<p>Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>. Because it is not known whether amide-type local anesthetics may trigger this reaction and because the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for management should be available. Early unexplained signs of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may precede temperature elevation. Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and prompt institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene. (Consult dantrolene sodium intravenous package insert before using.)</p>
<p><span class="Italics"><span class="Emphasis">Use in Head and Neck Area:</span></span> Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental, and stellate <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. The injection procedures require the utmost care. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and cardiovascular stimulation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. They may also be due to puncture of the dural sheath of the optic nerve during retrobulbar block with diffusion of any local anesthetic along the subdural space to the midbrain. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded. (See <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>.)</p>
<p><span class="Italics"><span class="Emphasis">Use in Ophthalmic Surgery:</span></span> Clinicians who perform retrobulbar blocks should be aware that there have been reports of <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> following local anesthetic injection. Prior to retrobulbar block, as with all other regional procedures, the immediate availability of equipment, drugs, and personnel to manage <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and cardiac stimulation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be assured (see also <span class="Bold"><span class="Emphasis">WARNINGS</span></span> and <span class="Italics"><span class="Emphasis">Use In Head and Neck Area</span></span>, above). As with other anesthetic procedures, patients should be constantly monitored following ophthalmic blocks for signs of these adverse reactions, which may occur following relatively low total doses.</p>
<p>A concentration of 0.75% bupivacaine is indicated for retrobulbar block; however, this concentration is not indicated for any other peripheral nerve block, including the facial nerve, and not indicated for local infiltration, including the conjunctiva (see <span class="Bold"><span class="Emphasis">INDICATIONS AND USAGE</span></span> and <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>, <span class="Bold"><span class="Emphasis">General</span></span>). Mixing MARCAINE with other local anesthetics is not recommended because of insufficient data on the clinical use of such mixtures.</p>
<p>When MARCAINE 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clinically acceptable external ocular muscle <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>. Therefore, presence of <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span> rather than anesthesia alone should determine readiness of the patient for surgery.</p>
<p><span class="Italics"><span class="Emphasis">Use in Dentistry:</span></span> Because of the long duration of anesthesia, when MARCAINE 0.5% with epinephrine is used for dental injections, patients should be cautioned about the possibility of inadvertent <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> to tongue, lips, and buccal mucosa and advised not to chew solid foods or test the anesthetized area by biting or probing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="f51dab39-d8c4-46f5-9c49-ccde13a6ea80"></a><a name="section-29.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Information for Patients:</span></span> When appropriate, patients should be informed in advance that they may experience temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and motor activity, usually in the lower half of the body, following proper administration of caudal or epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the package insert of MARCAINE.</p>
<p>Patients receiving dental injections of MARCAINE should be cautioned not to chew solid foods or test the anesthetized area by biting or probing until anesthesia has worn off (up to 7 hours).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="a8c38656-5297-4ac3-94a7-adaa9181457d"></a><a name="section-29.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Clinically Significant Drug Interactions:</span></span> The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.</p>
<p>Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
<p>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="b032b9d7-4ded-4722-b58b-b1000b75ea9c"></a><a name="section-29.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></span> Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine hydrochloride have not been conducted. The mutagenic potential and the effect on fertility of bupivacaine hydrochloride have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="c7ea0acc-07bd-4409-b3ae-56f3a4777114"></a><a name="section-29.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pregnancy Category C:</span></span> There are no adequate and well-controlled studies in pregnant women.  MARCAINE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  Bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses.  This does not exclude the use of MARCAINE at term for obstetrical anesthesia or <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. (See<span class="Bold"><span class="Emphasis"> Labor and Delivery</span></span>)</p>
<p>Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, &amp; 40 mg/kg and to rabbits at doses of 1.3, 5.8, &amp; 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate).  The high doses are comparable to the daily maximum recommended human dose (MRHD) of 400 mg/day on a mg/m<span class="Sup">2</span> body surface area (BSA) basis.  No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality.  An increase in embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> was observed in rabbits at the high dose in the absence of maternal toxicity with the fetal No Observed Adverse Effect Level representing approximately 1/5th the MRHD on a BSA basis.</p>
<p>In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, &amp; 40 mg/kg mg/kg/day, decreased pup survival was observed at the high dose.  The high dose is comparable to the daily MRHD of 400 mg/day on a BSA basis.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="d58f3bc9-9b1b-43de-9a56-90f73b3a1b16"></a><a name="section-29.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Labor and Delivery:</span></span> SEE BOXED WARNING REGARDING OBSTETRlCAL USE OF 0.75% MARCAINE.</p>
<p>MARCAINE is contraindicated for obstetrical paracervical block anesthesia.</p>
<p>Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity. (See <span class="Bold"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>, <span class="Bold"><span class="Emphasis">Pharmacokinetics</span></span>.) The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function.</p>
<p>Maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.</p>
<p>Epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.</p>
<p>The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. This has not been reported with bupivacaine.</p>
<p>It is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. To do this, the patient must be maintained in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position or a blanket roll or sandbag may be placed beneath the right hip and gravid uterus displaced to the left.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="dabb542a-1b2d-435b-8b2b-dad544ac3379"></a><a name="section-29.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Nursing Mothers:</span></span> Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Because of the potential for serious adverse reactions in nursing infants from bupivacaine, a decision should be made whether to discontinue nursing or not administer bupivacaine, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="fcbc1540-f034-4e88-8874-0fb7afd024be"></a><a name="section-29.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pediatric Use:</span></span> Until further experience is gained in pediatric patients younger than 12 years, administration of MARCAINE in this age group is not recommended. Continuous infusions of bupivacaine in children have been reported to result in high systemic levels of bupivacaine and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; high plasma levels may also be associated with cardiovascular abnormalities. (See <span class="Bold"><span class="Emphasis">WARNINGS</span></span>, <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>, and <span class="Bold"><span class="Emphasis">OVERDOSAGE</span></span>.)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="e2a8f36e-bcd3-45b8-b8f7-abd0f098efd1"></a><a name="section-29.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="Emphasis">Geriatric Use:</span></span> Patients over 65 years, particularly those with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, may be at increased risk for developing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> while undergoing anesthesia with MARCAINE. (See <span class="Bold"><span class="Emphasis">ADVERSE REACTIONS</span></span>.)</p>
<p>Elderly patients may require lower doses of MARCAINE. (See <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>, <span class="Bold"><span class="Emphasis">Epidural Anesthesia</span></span> and <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>.)</p>
<p>In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients. (See <span class="Bold"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>.)</p>
<p>This product is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="dbbf1ebe-8529-4e39-92d6-683fa1a4af49"></a><a name="section-30"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reactions to MARCAINE are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.</p>
<p>The most commonly encountered acute adverse experiences which demand immediate counter-measures are related to the central nervous system and the cardiovascular system. These adverse experiences are generally dose related and due to high plasma levels which may result from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional subarachnoid injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) may result in underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (“Total or High Spinal?). Also, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> due to loss of sympathetic tone and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> or underventilation due to cephalad extension of the motor level of anesthesia may occur. This may lead to secondary <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if untreated. Patients over 65 years, particularly those with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, may be at increased risk for experiencing the hypotensive effects of MARCAINE. Factors influencing plasma protein binding, such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, systemic diseases which alter protein production, or competition of other drugs for protein binding sites, may diminish individual tolerance.</p>
<br><p><span class="Bold"><span class="Emphasis">Central Nervous System Reactions:</span></span> These are characterized by excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> may occur, possibly proceeding to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. However, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> being the first manifestation of an adverse reaction. This may quickly be followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Other central nervous system effects may be <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and constriction of the pupils.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with the use of local anesthetics varies with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occurred in approximately 0.1% of local anesthetic administrations.</p>
<br><p><span class="Bold"><span class="Emphasis">Cardiovascular System Reactions:</span></span> High doses or unintentional intravascular injection may lead to high plasma levels and related <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium, decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, heartblock, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. (See <span class="Bold"><span class="Emphasis">WARNINGS</span></span>, <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>, and <span class="Bold"><span class="Emphasis">OVERDOSAGE</span></span>.)</p>
<br><p><span class="Bold"><span class="Emphasis">Allergic:</span></span> Allergic-type reactions are rare and may occur as a result of sensitivity to the local anesthetic or to other formulation ingredients, such as the antimicrobial preservative methylparaben contained in multiple-dose vials or sulfites in epinephrine-containing solutions. These reactions are characterized by signs such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, elevated temperature, and possibly, anaphylactoid-like symptomatology (including severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>). Cross sensitivity among members of the amide-type local anesthetic group has been reported. The usefulness of screening for sensitivity has not been definitely established.</p>
<br><p><span class="Bold"><span class="Emphasis">Neurologic:</span></span> The incidences of adverse <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic reactions</span> associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient. Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.</p>
<p>In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter or needle may occur. Subsequent adverse effects may depend partially on the amount of drug administered intrathecally and the physiological and physical effects of a dural puncture. A high spinal is characterized by <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the legs, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span>, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p>Neurologic effects following epidural or caudal anesthesia may include spinal block of varying magnitude (including high or total spinal block); <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> secondary to spinal block; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; fecal and <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>; loss of perineal sensation and sexual function; persistent anesthesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the lower extremities and loss of sphincter control all of which may have slow, incomplete, or no recovery; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>; septic <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>; <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningismus</span>; slowing of labor; increased incidence of forceps delivery; and cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.</p>
<p>Neurologic effects following other procedures or routes of administration may include persistent anesthesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, all of which may have slow, incomplete, or no recovery.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ba7bf191-5a9e-42af-a1c9-7383d0a674d2"></a><a name="section-31"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution. (See <span class="Bold"><span class="Emphasis">ADVERSE REACTIONS</span></span>, <span class="Bold"><span class="Emphasis">WARNINGS</span></span>, and <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>.)</p>
<br><p><span class="Bold"><span class="Emphasis">Management of Local Anesthetic Emergencies:</span></span> The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.</p>
<p><span class="Italics"><span class="Emphasis">The first step in the management of systemic toxic reactions, as well as underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintentional subarachnoid injection of drug solution, consists of </span></span><span class="Bold"><span class="Emphasis">immediate</span></span><span class="Italics"><span class="Emphasis"> attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask.</span></span> This may prevent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if they have not already occurred.</p>
<p>If necessary, use drugs to control the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. A 50 mg to 100 mg bolus IV injection of succinylcholine will paralyze the patient without depressing the central nervous or cardiovascular systems and facilitate ventilation. A bolus IV dose of 5 mg to 10 mg of diazepam or 50 mg to 100 mg of thiopental will permit ventilation and counteract central nervous system stimulation, but these drugs also depress central nervous system, respiratory, and cardiac function, add to postictal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and may result in <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated. Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids, and when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).</p>
<p>Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.</p>
<p>Recent clinical data from patients experiencing local anesthetic-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> demonstrated rapid development of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> with bupivacaine within a minute of the onset of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. These observations suggest that oxygen consumption and <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> production are greatly increased during local anesthetic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and emphasize the importance of immediate and effective ventilation with oxygen which may avoid <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>If not treated immediately, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> with simultaneous <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> plus myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> from the direct effects of the local anesthetic may result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Respiratory abnormalities, including <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, may occur. Underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if ventilatory support is not instituted. <span class="Italics"><span class="Emphasis">If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur, successful outcome may require prolonged resuscitative efforts.</span></span></p>
<p>The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore during treatment of systemic toxicity, maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> following regional block, the parturient should be maintained in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position if possible, or manual displacement of the uterus off the great vessels be accomplished.</p>
<p>The mean <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. The intravenous and subcutaneous LD<span class="Sub">50</span> in mice is 6 mg/kg to 8 mg/kg and 38 mg/kg to 54 mg/kg respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ed5aeeb8-9c32-4f27-93df-4102d6cb57dc"></a><a name="section-32"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. The smallest dose and concentration required to produce the desired result should be administered. Dosages of MARCAINE should be reduced for elderly and/or debilitated patients and patients with cardiac and/or liver disease. The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should be used when feasible.</p>
<p>For specific techniques and procedures, refer to standard textbooks.</p>
<p>There have been adverse event reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  MARCAINE is not approved for this use (see <span class="Bold"><span class="Emphasis">WARNINGS</span></span> and <span class="Bold"><span class="Emphasis">DOSAGE AND ADMINISTRATION</span></span>).</p>
<p>In recommended doses, MARCAINE produces complete sensory block, but the effect on motor function differs among the three concentrations.</p>
<br><p>0.25%—when used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> is not important, or when another means of providing <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> is used concurrently. Onset of action may be slower than with the 0.5% or 0.75% solutions.</p>
<p>0.5%— provides motor blockade for caudal, epidural, or nerve block, but <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> may be inadequate for operations in which complete <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> is essential.</p>
<p>0.75%—produces complete motor block. Most useful for epidural block in abdominal operations requiring complete <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span>, and for retrobulbar anesthesia. Not for obstetrical anesthesia.</p>
<br><p>The duration of anesthesia with MARCAINE is such that for most indications, a single dose is sufficient.</p>
<p>Maximum dosage limit must be individualized in each case after evaluating the size and physical status of the patient, as well as the usual rate of systemic absorption from a particular injection site. Most experience to date is with single doses of MARCAINE up to 225 mg with epinephrine 1:200,000 and 175 mg without epinephrine; more or less drug may be used depending on individualization of each case.</p>
<p>These doses may be repeated up to once every three hours. In clinical studies to date, total daily doses have been up to 400 mg. Until further experience is gained, this dose should not be exceeded in 24 hours. The duration of anesthetic effect may be prolonged by the addition of epinephrine.</p>
<p>The dosages in Table 1 have generally proved satisfactory and are recommended as a guide for use in the average adult. These dosages should be reduced for elderly or debilitated patients. Until further experience is gained, MARCAINE is not recommended for pediatric patients younger than 12 years. MARCAINE is contraindicated for obstetrical paracervical blocks, and is not recommended for intravenous regional anesthesia (Bier Block).</p>
<p><span class="Italics"><span class="Emphasis">Use in Epidural Anesthesia:</span></span> During epidural administration of MARCAINE, 0.5% and 0.75% solutions should be administered in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. In obstetrics, only the 0.5% and 0.25% concentrations should be used; incremental doses of 3 mL to 5 mL of the 0.5% solution not exceeding 50 mg to 100 mg at any dosing interval are recommended. Repeat doses should be preceded by a test dose containing epinephrine if not contraindicated. Use only the single-dose ampuls and single-dose vials for caudal or epidural anesthesia; the multiple-dose vials contain a preservative and therefore should not be used for these procedures.</p>
<p><span class="Italics"><span class="Emphasis">Test Dose for Caudal and Lumbar Epidural Blocks: </span></span>The Test Dose of MARCAINE (0.5% bupivacaine with 1:200,000 epinephrine in a 3 mL ampul) is recommended for use as a test dose when clinical conditions permit prior to caudal and lumbar epidural blocks. This may serve as a warning of unintended intravascular or subarachnoid injection. (See <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>.) The pulse rate and other signs should be monitored carefully immediately following each test dose administration to detect possible intravascular injection, and adequate time for onset of spinal block should be allotted to detect possible intrathecal injection. An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or cardiovascular effects from the epinephrine. (See <span class="Bold"><span class="Emphasis">WARNINGS</span></span> and <span class="Bold"><span class="Emphasis">OVERDOSAGE</span></span>.)</p>
<p><span class="Italics"><span class="Emphasis">Use in Dentistry:</span></span> The 0.5% concentration with epinephrine is recommended for infiltration and block injection in the maxillary and mandibular area when a longer duration of local anesthetic action is desired, such as for oral surgical procedures generally associated with significant <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>. The average dose of 1.8 mL (9 mg) per injection site will usually suffice; an occasional second dose of 1.8 mL (9 mg) may be used if necessary to produce adequate anesthesia after making allowance for 2 to 10 minutes onset time. (See <span class="Bold"><span class="Emphasis">CLINICAL PHARMACOLOGY</span></span>.) The lowest effective dose should be employed and time should be allowed between injections; it is recommended that the total dose for all injection sites, spread out over a single dental sitting, should not ordinarily exceed 90 mg for a healthy adult patient (ten 1.8 mL injections of 0.5% MARCAINE with epinephrine). Injections should be made slowly and with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspirations</span>. Until further experience is gained, MARCAINE in dentistry is not recommended for pediatric patients younger than 12 years.</p>
<p>Unused portions of solution not containing preservatives, i.e., those supplied in single-dose ampuls and single-dose vials, should be discarded following initial use.</p>
<p>This product should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Solutions which are discolored or which contain particulate matter should not be administered.</p>
<br><table>
<caption><span>Table 1. Recommended Concentrations and Doses of MARCAINE</span></caption>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Type of<br>
                Block</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Conc.</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">Each Dose </td>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom">Motor <br>
                Block<span class="Sup">1</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">(mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">(mg)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">Local</p>
<p>infiltration</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.25%<span class="Sup">4</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> up to<br>
                max.</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">up to <br>
                max.</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">—</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top">Epidural <br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.75%<span class="Sup">2,4</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10-20 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">75-150 </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">complete </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5%<span class="Sup">4</span> <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10-20 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50-100<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">moderate <br>
                to complete</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.25%<span class="Sup">4</span> <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10-20 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25-50 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">partial<br>
                to moderate</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Caudal <br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.5%<span class="Sup">4</span> <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15-30 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">75-150 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">moderate <br>
                to complete</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.25%<span class="Sup">4</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15-30 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37.5-75 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">moderate</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Peripheral <br>
                 nerves<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.5%<span class="Sup">4</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 5 to<br>
                max.</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25 to <br>
                max.</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">moderate<br>
                to complete</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.25%<span class="Sup">4</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5 to <br>
                 max.</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 12.5 to<br>
                 max.</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">moderate<br>
                to complete</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Retrobulbar<span class="Sup">3</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.75%<span class="Sup">4</span> </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 2-4</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15-30 </td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">complete</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Sympathetic </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.25%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20-50 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50-125 </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">— </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Dental<span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.5%<br>
                 w/epi</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.8-3.6 <br>
                 per site</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9-18 <br>
                per site</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">—</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Epidural<span class="Sup">3</span><br>
                Test Dose</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> 0.5%<br>
                 w/epi</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2-3</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10-15 <br>
                (10-15 micrograms epinephrine)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">—</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5">
<p class="First"><span class="Sup">1</span>With continuous (intermittent) techniques, repeat doses increase the degree of motor block. The first repeat dose of 0.5% may produce complete motor block. Intercostal nerve block with 0.25% may also produce complete motor block for intra-abdominal surgery.</p>
<p><span class="Sup">2</span>For single-dose use, not for intermittent epidural technique. Not for obstetrical anesthesia.</p>
<p><span class="Sup">3</span>See <span class="Bold"><span class="Emphasis">PRECAUTIONS</span></span>.</p>
<p><span class="Sup">4</span>Solutions with or without epinephrine.</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ca602154-ce12-432e-b796-0aef70a261d9"></a><a name="section-33"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold"><span class="Emphasis">These solutions are not for spinal anesthesia.</span></span></p>
<br><p>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</p>
<br><p><span class="Italics"><span class="Emphasis">MARCAINE</span></span> ―Solutions of MARCAINE that do not contain epinephrine may be autoclaved. Autoclave at 15-pound pressure, 121°C (250°F) for 15 minutes.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">NDC No.</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Container</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Fill</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Quantity</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="middle">0.25%—Contains 2.5 mg bupivacaine hydrochloride per mL.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1559-10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1559-30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">30 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1587-50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Multiple-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">50 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">0.5%—Contains 5 mg bupivacaine hydrochloride per mL.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1560-10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1560-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">30 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1610-50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Multiple-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">50 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom">0.75%—Contains 7.5 mg bupivacaine hydrochloride per mL.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1582-10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1582-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">30 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
</tbody></table>
<p><span class="Italics"><span class="Emphasis">MARCAINE with epinephrine 1:200,000</span></span> (as bitartrate)―<span class="Underline"><span class="Emphasis">Solutions of MARCAINE that contain epinephrine should not be autoclaved and should be protected from light. Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><span class="Bold"><span class="Emphasis">NDC No.</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Container</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Fill</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><span class="Emphasis">Quantity</span></span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle">0.25% with epinephrine 1:200,000—Contains 2.5 mg bupivacaine hydrochloride per mL.</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1746-10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1746-30</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">30 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1752-50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Multiple-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">50 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle">
<br>
                0.5% with epinephrine 1:200,000—Contains 5 mg bupivacaine hydrochloride per mL.</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1749-03</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose ampuls</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">3 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1749-10</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1749-29</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Single-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">30 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 10</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">0409-1755-50</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Multiple-dose vials</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">50 mL</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">box of 1</td>
</tr>
</tbody></table>
<p>Revised: 10/2011</p>
<p> </p>
<p>Printed in USA                           EN-2916         </p>
<p>Hospira, Inc., Lake Forest, IL 60045 USA</p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="s52"></a><a name="section-34"></a><p></p>
<p class="First">Section Text</p>
<p><span class="Bold">Active Ingredient                                  Purpose</span></p>
<p>Povidone Iodine 10% v/v                        Antiseptic                            <br></p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="s53"></a><a name="section-35"></a><p></p>
<h1>Purpose:</h1>
<p class="First"><br>Purpose:<br></p>
<ul>
<li>First aid antiseptic to help prevent <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span> in minor cuts, scrapes and <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</li>
<li>For preparation of the skin prior to surgery.</li>
<li>Helps reduce bacteria that can potentially cause <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s54"></a><a name="section-36"></a><p></p>
<h1>Warnings:</h1>
<p class="First">Section Text</p>
<ul><li>
<span class="Bold">FOR EXTERNAL USE ONLY</span><br>
</li></ul>
</div>
<div class="Section" data-sectionCode="50570-1">
<a name="s55"></a><a name="section-37"></a><p></p>
<h1>Do not use:</h1>
<br><ul>
<li>As a first aid antiseptic for more than 1 week.</li>
<li>In the eyes.</li>
<li>Over large areas of the body.<br>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="50569-3">
<a name="s56"></a><a name="section-38"></a><p></p>
<h1>Ask a doctor before use if you have:</h1>
<p class="First"><br></p>
<ul>
<li>Deep puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span></li>
<li>Animal bites</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span><br>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="50566-9">
<a name="s57"></a><a name="section-39"></a><p></p>
<h1>Stop Use:</h1>
<p class="First"><br></p>
<ul>
<li>If irritation and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> develop</li>
<li>If condition persists for more than 72 hours, consult a physician.<br>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="s58"></a><a name="section-40"></a><p></p>
<h1>Keep Out Of Reach Of Children</h1>
<p class="First"><span class="Bold">Keep out of reach of children.</span>If swallowed, get medical help or contact a Poison Control Center.<br></p>
<p><span class="Bold"><br></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s59"></a><a name="section-41"></a><p></p>
<h1>Directions Povidone iodine:</h1>
<p class="First">Tear at notch, remove applicator, use only once.</p>
<p><span class="Bold">As a first aid antiseptic</span></p>
<ul>
<li>clean affected area</li>
<li>apply 1 to 3 times daily</li>
<li>may be covered with a sterile bandage, if bandaged let dry.</li>
</ul>
<br><span class="Bold">For preoperative patient skin preparation<br><br></span><ul>
<li>clean area</li>
<li>apply to operative site prior to surgery using the applicator<br>
</li>
</ul>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-42"></a><p></p>
<h1>Other information:</h1>
<p class="First">Store at room temperature.</p>
<p>Avoid excessive heat<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s61"></a><a name="section-43"></a><p></p>
<p class="First">For use as an <br></p>
<ul>
<li>first aid antiseptic <br>
</li>
<li>pre-operative skin preperation<br>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="s62"></a><a name="section-44"></a><p></p>
<h1>Inactive Ingredients</h1>
<p class="First">Inactive ingredients: nonoxynol-9, water<br></p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="i4i_OTC_Active_Ingredient_id_bd991a0b-fdf3-4210-a559-8be5d74f69ab"></a><a name="section-45"></a><p></p>
<h1>Active ingredient</h1>
<p class="First">Isopropyl Alcohol 70% v/v<br></p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="i4i_OTC_Purpose_id_68967d10-7557-4f16-bcc9-fead4b911c53"></a><a name="section-46"></a><p></p>
<h1>Purpose</h1>
<p class="First">Antiseptic</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_458d385e-40b4-4f69-b21f-8be762572a3b"></a><a name="section-47"></a><p></p>
<h1>Uses</h1>
<p class="First">For first aid to decrease germs in</p>
<ul>
<li>minor cuts</li>
<li>scrapes</li>
<li><span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span></li>
</ul>
<p>For preparation of the skin prior to injection</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_d71ed11d-8921-42bd-b11a-7ecba9eb61c7"></a><a name="section-48"></a><p></p>
<h1>Warnings</h1>
<p class="First"><span class="Bold">For external use only</span></p>
<p><span class="Bold">Flammable - keep away from fire or flame</span></p>
<div class="Section" data-sectionCode="50570-1">
<a name="i4i_OTC_Do_not_use_id_fb5ddee8-0adf-4658-9553-9c7725cc8aee"></a><a name="section-48.1"></a><p></p>
<h2>Do not use</h2>
<p class="First">with electrocautery procedures</p>
</div>
<div class="Section" data-sectionCode="50567-7">
<a name="i4i_OTC_When_Using_id_79f29cbb-ac17-40b5-ab3d-77cd2845b305"></a><a name="section-48.2"></a><p></p>
<h2>When using this product do not</h2>
<ul>
<li>get into eyes</li>
<li>apply over large areas of the body</li>
<li>in case of deep or puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, animal bites or serious <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> consult a doctor</li>
</ul>
</div>
<div class="Section" data-sectionCode="50566-9">
<a name="i4i_OTC_Stop_Use_id_14379cb0-702b-43b5-8d7a-d81337b231c3"></a><a name="section-48.3"></a><p></p>
<h2>Stop use and ask a doctor if</h2>
<ul>
<li>condition persists or gets worse or lasts for more than 72 hours</li>
<li>do not use longer than 1 week unless directed by a doctor</li>
</ul>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="i4i_OTC_Keep_Away_Children_id_6281159d-6496-4372-b97b-c20af304baa6"></a><a name="section-48.4"></a><p></p>
<h2>Keep out of reach of children.</h2>
<p class="First">If swallowed, get medical help or contact a Poison Control Center right away.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5750d15e-683a-4572-b2e8-bff0a2eb29d6"></a><a name="section-49"></a><p></p>
<h1>Directions</h1>
<ul>
<li>apply to skin as needed</li>
<li>discard after single use</li>
</ul>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a11fdb34-d958-4e44-82c8-197270227b99"></a><a name="section-50"></a><p></p>
<h1>Other information</h1>
<p class="First">Protect from freezing and avoid excessive heat</p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="i4i_inactive_ingredients_id_3ef9a0db-3a14-4a6e-9183-6b8d44953eaf"></a><a name="section-51"></a><p></p>
<h1>Inactive ingredient</h1>
<p class="First">Water</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s63"></a><a name="section-52"></a><p></p>
<h1>Principal Display Panel – Vial Label
</h1>
<p class="First"><span class="Bold">10 mL (25 mg) Single-dose vial NDC 0409-1559-10</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Preservative-Free</span></p>
<p><span class="Bold">Marcaine</span><span class="Bold"><span class="Sup">®
</span></span><span class="Bold">0.25%</span></p>
<p>bupivacaine HCl injection, USP
</p>
<p><span class="Bold">for INFILTRATION, NERVE BLOCK, CAUDAL,</span></p>
<p><span class="Bold">and  EPIDURAL ANESTHESIA</span></p>
<p><span class="Bold">NOT FOR SPINAL ANESTHESIA.   Hospira</span></p>
<div class="Figure">
<a name="f06"></a><img alt="Principal Display Panel – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s64"></a><a name="section-53"></a><p></p>
<h1>Principal Display Panel – Ampule Label
</h1>
<p class="First">5mL NDC 0409-4713-65
</p>
<p><span class="Bold">Preservative-Free</span></p>
<p><span class="Bold">1% LIDOCAINE HCl</span></p>
<p>Injection, USP
</p>
<p><span class="Bold">10 mg/mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p>HOSPIRA, INC.
</p>
<p>LAKE FOREST, IL 60045 USA
</p>
<p>Hospira
</p>
<div class="Figure">
<a name="f07"></a><img alt="Principal Display Panel – Ampule Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s65"></a><a name="section-54"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Label
</h1>
<p class="First">NDC 0517-0720-01
</p>
<p><span class="Bold">BETAMETHASONE  </span></p>
<p><span class="Bold">SODIUM PHOSPHATE and </span></p>
<p><span class="Bold">BETAMETHASONE ACETATE</span></p>
<p> Injectable Suspension, USP
</p>
<p><span class="Bold">30 mg*/5 mL (</span>6 mg*/mL)
</p>
<p><span class="Bold">5 mL</span> MULTIPLE DOSE VIAL
</p>
<p><span class="Bold">Sterile</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">AMERICAN  </span></p>
<p><span class="Bold">REGENT, INC.  </span></p>
<p>SHIRLEY, NY  11967
</p>
<div class="Figure">
<a name="f08"></a><img alt="PRINCIPAL DISPLAY PANEL - 5 mL Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s66"></a><a name="section-55"></a><p></p>
<h1>Principal Display Panel – Pouch Label
</h1>
<p class="First"><span class="Bold">3 Swabs</span></p>
<p><span class="Bold">Povidone-Iodine </span></p>
<p><span class="Bold">Swabsticks</span></p>
<p><span class="Bold">dynarex</span><span class="Bold"><span class="Sup">®</span></span></p>
<p>Antiseptic/Germicide
</p>
<p>For External Use Only
</p>
<p><span class="Bold">Made In Israel</span></p>
<p>Reorder <span class="Bold">No. 1202</span></p>
<div class="Figure">
<a name="f09"></a><img alt="Principal Display Panel – Pouch Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s67"></a><a name="section-56"></a><p></p>
<h1>Principal Display Panel –
</h1>
<p class="First">NDC:53329-820-09
</p>
<p>CURAD<span class="Sup">®</span></p>
<p>WE HELP HEAL
</p>
<p><span class="Bold">ALCOHOL SWABS</span></p>
<p><span class="Bold">With 70% isopropyl alcohol</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> guaranteed</span></p>
<p>(unless package is damaged or opened)
</p>
<p><span class="Bold">Antiseptic</span></p>
<p>For external use only.
</p>
<div class="Figure">
<a name="f10"></a><img alt="Principal Display Panel –
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s68"></a><a name="section-57"></a><p></p>
<h1>Principal Display Panel – Kit Label
</h1>
<p class="First"><span class="Bold">NDC 76420-782-01        RX-Only</span></p>
<p><span class="Bold">Marbeta-L</span><span class="Bold"><span class="Sup">TM</span></span></p>
<p><span class="Bold">Kit Contains:<br></span>1 Marcaine<span class="Sup">TM</span> 0.25% (10mL)*
</p>
<p>1 Betamethasone Sodium Phosphate and Betamethasone 6mg/mL (5mL)*
</p>
<p>1 Lidocaine HCl Injection, USP 1% (5mL)*
</p>
<p>1 Povidone-Iodine Swabsticks (3 Swabs)
</p>
<p>4 Isopropyl Alcohol 70% Prep Pads
</p>
<p>1 Pair of Nitrile Powder Free Sterile Gloves (Non-Latex)* (Size 7.5)
</p>
<p>1 Adhesive Bandage
</p>
<p>Non Sterile 4x4 Gauze
</p>
<p>Needles and Syringes Not Included
</p>
<p><span class="Italics">Distributed by:</span></p>
<p><span class="Bold">Enovachem<br></span>MANUFACTURING<br>Torrance, CA 90501
</p>
<p>LOT:
</p>
<p>EXP:
</p>
<div class="Figure">
<a name="f11"></a><img alt="Principal Display Panel – Kit Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a6a3871-4e02-47f9-a20e-a256b3f3c498&amp;name=mar0a-0000-11.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MARBETA L KIT 		
					</strong><br><span class="contentTableReg">betamethasone sodium phosphate, betamethasone acetate, lidocaine hydrochloride, bupivacaine hydrochloride, povidine iodine, isopropyl alcohol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76420-782</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76420-782-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, MULTI-DOSE </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 AMPULE </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">10 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem">1 PACKET </td>
<td class="formItem">0.9 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 5</strong></td>
<td class="formItem">4 POUCH </td>
<td class="formItem">20 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 5</td></tr>
<tr><td class="contentTableTitle">
<strong>BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE 		
					</strong><br><span class="contentTableReg">betamethasone sodium phosphate and betamethasone acetate injection, suspension</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-0720</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRA-ARTICULAR, INTRAMUSCULAR, INTRALESIONAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Betamethasone Sodium Phosphate</strong> (Betamethasone) </td>
<td class="formItem">Betamethasone</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Betamethasone Acetate</strong> (Betamethasone) </td>
<td class="formItem">Betamethasone Acetate</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Dibasic Anhydrous </strong></td>
<td class="formItem">7.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Monobasic, Monohydrate</strong></td>
<td class="formItem">3.4 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Edetate Disodium</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Benzalkonium Chloride</strong></td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-0720-01</td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090747</td>
<td class="formItem">04/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 5</td></tr>
<tr><td class="contentTableTitle">
<strong>LIDOCAINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">lidocaine hydrochloride injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-4713</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INFILTRATION</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Lidocaine Hydrochloride</strong> (Lidocaine) </td>
<td class="formItem">Lidocaine Hydrochloride Anhydrous</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-4713-65</td>
<td class="formItem">5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080408</td>
<td class="formItem">09/28/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 5</td></tr>
<tr><td class="contentTableTitle">
<strong>MARCAINE 		
					</strong><br><span class="contentTableReg">bupivacaine hydrochloride injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-1559</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">EPIDURAL, INFILTRATION</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Bupivacaine Hydrochloride</strong> (Bupivacaine) </td>
<td class="formItem">Bupivacaine Hydrochloride Anhydrous</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-1559-10</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016964</td>
<td class="formItem">09/08/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 5</td></tr>
<tr><td class="contentTableTitle">
<strong>POVIDINE IODINE 		
					</strong><br><span class="contentTableReg">povidine iodine swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67777-130</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Povidone-Iodine</strong> (Iodine) </td>
<td class="formItem">Iodine</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nonoxynol-9</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67777-130-02</td>
<td class="formItem">0.9 mL in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">OTC monograph final</td>
<td class="formItem">part333C</td>
<td class="formItem">05/10/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 5 of 5</td></tr>
<tr><td class="contentTableTitle">
<strong>ISOPROPYL ALCOHOL 		
					</strong><br><span class="contentTableReg">isopropyl alcohol swab</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53329-820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Isopropyl Alcohol</strong> (Isopropyl Alcohol) </td>
<td class="formItem">Isopropyl Alcohol</td>
<td class="formItem">70 mL  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53329-820-09</td>
<td class="formItem">5 mL in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">OTC monograph not final</td>
<td class="formItem">part333A</td>
<td class="formItem">01/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090747</td>
<td class="formItem">04/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Asclemed USA, Inc.
							(059888437)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Asclemed USA, Inc.</td>
<td class="formItem"></td>
<td class="formItem">059888437</td>
<td class="formItem">REPACK(76420-782)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2466e8b9-7011-4028-9ba3-8cc972290aa2</div>
<div>Set id: 9a6a3871-4e02-47f9-a20e-a256b3f3c498</div>
<div>Version: 2</div>
<div>Effective Time: 20140812</div>
</div>
</div> <div class="DistributorName">Asclemed USA, Inc.</div></p>
</body></html>
